The cell and gene therapy market has seen a revolutionary transition in recent years, with advancements in scientific research and novel methods of treatment driving a rise in development activities. This has resulted in an increase in the number of cell and gene therapy choices available to patients suffering from a wide range of diseases, from rare genetic disorders to more prevalent diseases. With gene therapy quickly extending outside its traditional emphasis on rare diseases, the market is primed for tremendous development and presents an attractive opportunity for biotechnology and pharmaceutical companies to have a meaningful impact on patient outcomes. As a re...
